
Index

A

Aasparaginase, 185
AAV-2, 81, 86, 87, 91
ABC Transporters, 142, 148
ABC-B11, 147
ABC-G2, 146
ABC-transport, 109
Absorption, 349–351
Abzyme, 331
Acivicin, 118
Actin, 14
Actinomycin, 193
Active transport, 107, 116
Acyclovir, 118, 121
ADCC, 315
Adeno-associated virus (AAV), 81, 82, 84, 85, 87, 90
Adenocarcinoma, 197
ADEPT, 330
Adjuvant, 52
Adriamycin, 193
Albumin, 184
Alexa Flour™, 488, 82
Alopecia, 194
Alpha emitter, 325
Aluminum salts (alum), 52
Amino acids transporters, 117
Aminolysis, 182
Angiogenesis, 181
Angiogenic marker, 317
Antennapedia transcription factor (ANTP), 96, 102
Antibody fragment, 316
Antibody specificity, 316
Antibody-based tumor targeting, 312
Antibody-binding affinity, 317
Antibody-dependent cell-mediated cytotoxicity (ADCC), 49

Antibody-dependent cellular cytotoxicity, 315
Antibody-directed enzyme-prodrug therapy, 330
Antigen Expression, 317
Antigen modulation, 318
Antigen presenting cell (APC), 287
 Fc receptor, 289
 loading, 292
 peptide epitopes, 292
 MHC, 287
 targeting, 291
 vector properties, 292
Anti-ICAM-1, 279, 281
Anti-idiotypic MAb, 315
ASBT, 122
ATP, 129
Auger emitter, 325
Automation, 345, 354
Avidin, 191

B

B cells, 48
B lymphocytes, 46
 function, 46
 memory cells, 48, 50
 plasma cells, 46
Baclofen, 118
Bacterial enterotoxins, 54
Barriers to DNA delivery, 67, 68
BCRP, 146
Beta emitter, 317, 325
Bexxar, 315
Bioavailability, 190
Biocompatible, 183, 187
Biodegradable, 187–189
Biotin, 97, 115, 116, 191
Bispecific antibody targeting, 332

- Bleomycin, 194, 196
Block copolymer, 4, 200
 diblock, 203
 triblock, 203
Blood–brain barrier, 103, 351, 356
 neurotoxicity, 131
Bloom strength, 191
BR96-doxorubicin conjugate (BR96-DOX), 324
Bradykinin, 181
BSEP, 147
Bystander effect, 317
- C**
- Caco-2, 166, 168–173, 177, 349–351, 356
Camptothecin, 116, 184, 186, 203
Carboplatin, 196
Carcinoma, 185, 197–198, 202
Cardiolipin, 194
Cardiotoxicity, 190, 196
Carrier-mediated transport 109, 114
Caspase-3, 98–99
Catalytic antibody, 316
Cationic lipids, 88
Cationic liposomes, 88, 89
Cationic microparticles, 268
Cationic submicron emulsions (CpG DNA delivery), 271
Caveolae, 15
Cell cycle, 25, 99
 abnormalities, 27
 clonal selection, 27
 differentiation, 27
 mutation, 27
 selection, 27
cancer drug targeting, 28
 modulator, 28
control, 26
 Cdk, 26
 CKI, 26
 external control, 26
phases, 25, 26
 gap, 25
 interphase, 25
 mitosis, 25
- Cell uptake, 356–357
Cell components, 9
 cytoplasm, 11
 cytoskeleton, 14
 endoplasmic reticulum, 12
 golgi apparatus, 13
 lysosomes, 13
 mitochondria, 13
 nucleus, 11
 organelles, 11
 peroxisomes, 13
 plasma membrane, 10
Cell-mediated immunity, 47, 48
Cellular barriers, 346
Channels
 aqueous, 11, 14
 ion, 17
 ligand-gated, 17
 mechanical-gated, 17
 voltage-gated, 17
Charge ratio, 89
Chemical conjugation, 97–98
Chemoimmunoconjugate, 321
Chimeric antibody, 313
Chitosan, 183, 186, 190, 205
Chlorambucil, 312
Chloramphenicol acetyl transferase, 195
Cholesterol, 122, 192, 196, 199
Cholesteryl hemisuccinate (CHEM), 88
Chromatography, 349–352, 354
Cisplatin, 188, 193, 196, 201
Class of MAb therapy, 315
Classes of P-gp inhibitors, 141
Clathrin-coated pits, 81, 84
Clinical trial, 183, 186, 196
CMC, 315
Cochleates, 56
Colchicine, 199
Complementarity determining regions (CDRs), 413
Complement-mediated cytotoxicity, 315
Complement-mediated cytotoxicity (CMC), 315
Copolymer, see Block copolymer
CpG DNA, 266

- Cutaneous barrier, 103
- Cyclosporin A, 100
- Cystic fibrosis TM conductance regulator, 109
- Cystic fibrosis, 109
- Cytochrome P450, 353–354
- Cytokines, 48, 49
 - colony-stimulating factors (CSF), 59
 - interferons (IFN), 48, 50
 - interleukins (IL), 49
 - tumor necrosis factor (TNF), 49
- Cytoplasm, 11
- Cytosine–phosphate–guanosine (CpG) motifs, 54, 56
- Cytosis, *see* Endocytosis
- Cytoskeleton, 14
- Cytosol, 11
- Cytotoxicity, 204
- D**
- DAB389IL2 (Ontak), 329
- Dactinomycin, 189
- Daunomycin, 193
- Daunorubicin, 192, 194, 203
- Daunoxome, 192
- Deglycosylation, 329
- Dendritic cell, 100
- Dermis, 278
- Dextran, 183, 186
- Dialysis, 202
- Diolcoylphosphatidic acid (DOPA), 88
- Diolcoylphosphatidylethanolamine, 87
- Disaccharide, 117
- DNA, 236–241
 - supercoiled, 238
 - vaccines, 237
- DNA degradation and Protection, 67
- DNA delivery, 69
 - cellular Barrier, 69
 - immunological Barrier, 72
 - physiological Barrier, 67
- DNA stability, 237–241
 - dehydration, 240–241
 - freeze–thawing, 238–240
- Double lipid bilayer, 11, 13
- Doxil, 195
- Doxorubicin, 183–184, 186, 188–190,
 - 194, 196, 203
 - dextran conjugated, 190
 - dimer, 201–202
- Drug delivery technology, 1
- Drug resistance, 140
- Drug targeting, 181, 217
 - artificial lipoprotein, 222
 - chylomicron, 218
 - HDL, 222
 - LDL, 220
 - acetylated, 221
 - anticancer, 220
 - brain, 221
 - lactosylated, 221
 - oxidized, 221
 - surface modified, 222
 - protein–carbohydrate complexes, 226
 - protein–nucleic acid complexes, 227
 - protein–protein complexes, 224
 - VLDL, 219
- Drug absorption barrier, 10, 11
- Duodenum, 283
- E**
- Edible vaccines, 54
- Efflux, 170
- Emulsions, 55
 - complete Freund's adjuvant (CFA),
 - 58, 266
 - incomplete Freund's adjuvant (IFA),
 - 56
 - MF59, 58, 266, 272
 - syntex adjuvant formulation-m (SAF-m),
 - 58
- Endocytosis, 4, 15, 69, 85, 86, 182, 191
- Endoplasmic reticulum, 12
- Endosomal release, 70
- Endosome, 2, 85, 88, 89, 91
- Endosome-disruptive properties, 4
- Endosomolytic, 89
- Enhanced permeation and retention (EPR), 68
- Enkephalin, 117
- Enterocyte, 166
- Epidermis, 278

Epirubicin, 203
EPR effect, 182, 195, 200–201, 204
Exocytosis, 16
Extracellular matrix, 181, 186

F

FITC-labeled ODN, 283
Fluorouracil, 199
Fructose, 116

G

Galactose, 116
Gamma emitter, 325
Gap junction, 17
Gelatin, 183, 191
Gene delivery systems, *see* nonviral vectors
Gene delivery, *see* DNA delivery
Gene expression control, 29
Gene expression, 28, 71
 local administration, 69
 process, 28
 DNA replication, 28
 transcription, 28
 translation, 28
 route of administration, 69
 systemic biodistribution, 69
Gene induction, 172
Genetic knock-out animals, 131, 132
Glucosamine, 205
Glucose transporter, 116, 123
GLUT, 116, 117
Glutathione, 203
Glycoprotein, 184
Glycosidic linkage, 187
Golgi apparatus, 13
Granulocytopenia, 190

H

Hairless guinea pig, 281
Hepatoma, 184–185, 193
Herpes simplex virus (HSV), 45
High throughput, 347, 349–351
HPMA copolymers, 12
Human immunodeficiency virus (HIV),
 51, 95–99, 103

Humanized antibody, 314
Humoral immunity, 45
Hyaluronic acid, 183
Hybridoma, 312
Hypoxia, 181

I

Immune stress molecule, 290
 endogenous, 290
 exogenous, 290
 hybrid, 290
 double stranded RNA (dsRNA), 290
Immuneeffector mechanism, 315
Immunoconjugate, 315
 distribution, 318
 immunological factors, 320
 pharmacological factors, 319
 physical and technical factors, 320
 physiological factors, 318
 selection criteria, 316
Immunoglobulin, 289
 complementarity determining region
 (CDR), 292
 constant domain, 292
 formulations, 299
 IgG class, 313
 mediated peptide delivery, 293
 recombinant, 291
Immunoliposome, 323
Immunostimulating complex (ISCOM),
 53, 54
Immunotoxin, 315, 328
In silico model, 353, 360
Inflammatory cytokines, 79
Influenza infection, 50
Influx, 169, 176
Innate immune protection, 267
Innate immunity, 48
 antigen-presenting cells (APCs), 46,
 48
 dendritic cells, 48
 Langerhans cells, 46, 54
 macrophages, 46, 48
 natural killer (NK) cells, 46
 phagocytosis, 48

- Integrity, 347
Intermediate filaments, 14
Interstitial pressure, 181
Intestinal absorption and bioavailability, 132
Intestinal metabolism, 173
Intestinal perfusion, 164
Intestinal permeability method, 163–166
Intracellular targeting, 55
Inverted hexagonal, 87
Iodixanol, 84
Ion channel, 107, 109
ISIS 2302. *See* Anti-ICAM-1
- K**
Kupffer cells, 189
- L**
LAT1, 118
Leucopenia, 189
Leukemia, 185, 187, 197, 202, 203
Lipid bilayer, 14
Lipid, 194
 cationic, 194
 1, 2-dioleoyl-3-trimethylammonium propane, 194
 lipofectin, 194
 dimyristylphosphatidylcholine, 194
 dioleoylphosphatidylethanolamine, 194
 dipalmitoylphosphatidylcholine, 194
 distearoylphosphatidylcholine, 194
Lipid-based oral drug delivery, 114
Lipoate, 115
Lipopeptides, 56
Lipophilicity, 351–352
Lipoplexes, 88, 183, 195
Lipoprotein, 217, 218
 artificial, 222, 223
 cancer drug delivery, 223
 gene delivery, 222
 nanoemulsion, 223
 palmitoyl poly-L-lysine (p-PLL), 223
 chylomicron, 218
 endogenous, 222
 HDL, 222
 LDL, 220
 VLDL, 219
Liposome, 53, 54, 56, 87, 88, 96, 101, 183, 192–199
 CpG DNA delivery, 268
 formulation, 56
 pH sensitive, 199
 physiochemical properties, 56
 routes of administration, 56
 stealth, 183, 195
 thermoresponsive, 199
 virosoemes, 57
Liver, 283
Log D. *See* Lipophilicity
Log P. *See* Lipophilicity
Lymphoid tissue, 53
 cutaneous tissues, 53
 gut-associated lymphoid tissue (GALT), 53
 lymph nodes, 46, 53
 mucosal-associated lymphoid tissues (MALT), 53
 Peyer's patches, 46
 spleen, 46
Lymphoma, 183, 185, 193
Lysosomes, 13
Lysosomolytic, 89
- M**
Major facilitator, 108
Major histocompatibility complex, 45
 MHC class I, 46
 MHC class II, 48, 267
Malignant cell, 181
MDCK, 173, 350–351, 356
MDR reversal, 140
Melanoma, 184–186, 189
Melphalan, 118
Membrane fusion, 17
Membrane protein, 109, 116
Metabolism, 353–356
Methotrexate, 193, 199
Micelles, 199

- critical micellar concentration, 200
- pH sensitive, 202
- preparation
 - ultrafiltration, 204
 - dialysis, 204
- thermoresponsive, 204
- Microparticles, 54
 - poly (lactide-co-glycolide) (PLG)
 - polymers, 55
 - spray-dried (SDM), 299
 - engineering, 299
 - aerodynamics, 303
 - kinetics, 303
 - stability, 303
 - IgG formulations, 303
 - FcγR targeting, 307
 - pulmonary delivery, 302
 - airway vs parenteral, 305
 - immunogenicity, 306
- Microtubules, 195
- Mitoxantrone, 189, 196
- Mononuclear phagocyte system, 189, 192
- MRP1, 144, 148
- MRP2, 144
- MRP3, 144
- MRP4, 145
- MRP5, 145
- MRP6, 145
- Mucositis, 196
- Multidrug resistance, 182, 189, 194, 203
- Multivariate analysis, 359
- Multivitamin transporter, 115
- Mutations, 181
- MXR, 146
- Myelosuppression, 196
- Mylotarg, 315
- N**
 - N*, *N*-dioleoyl-*N*, *N*-dimethylammoniumchloride (DODAC), 88
 - Nanoparticle, 96, 101, 187
 - CpG DNA delivery, 268
 - preparation, 188
 - double emulsion, 188
 - emulsification diffusion, 188
 - evaporation, 188
 - solvent displacement method, 191
 - reverse emulsion method, 191
 - diafiltration, 188
 - Natural particulates, 268
 - Necrosis, 181
 - Neocarzinostatin, 183–184
 - Neuropathy, 194
 - Neutropenia, 194
 - Niosomes, 183, 199
 - Nitric oxide, 181
 - Nonviral delivery strategies, 67
 - Nonviral vectors
 - stability, 242–255
 - dehydration, 250–255
 - glass formation, 247–249
 - liquid formulations, 242–243
 - lyophilization, see dehydration
 - particle isolation, 249
 - storage, 253–254
 - frozen, 243–249
 - Nuclear localization, 71
 - Nuclear localization signal (NLS), 96
 - Nuclease, 188, 190
 - Nucleic acid slot-blot method, 83
 - Nucleosides, 108, 118
- O**
 - Oligonucleotide, 81
 - antisense, 190
 - Oligopeptide, 183
 - Opsonization, 195
- P**
 - Paclitaxel, 184–185, 188, 204–205
 - PAMPA, 350
 - Pantothenate, 115, 116
 - Paracellular, 168
 - Parvovirus, 81
 - Passive targeting, 182, 194–195, 200
 - Passive transport, 139
 - Pathogen-associated molecular pattern (PAMP), 72
 - Penetratin-1, *See* Antennapedia transcription factor
 - Pentoxifyline, 199

- PepT1, 120, 121
Peptide transporter, 120, 121
Permeability, 349–351
Permeation mechanism, 168–171
P-glycoprotein, 347, 356
P-glycoprotein efflux activity, 4
P-glycoprotein, 135
 drug interactions, 135
 expression variability, 137
 function and mechanism, 130
 in vitro to in vivo correlation, 138
 induction and overexpression, 135
 inhibition, 140
 clinical development, 142
 inhibitor, 139
 modulation, 140
 mutations and polymorphisms, 137
 overall efficiency of active transport, 138
 placenta and teratogenicity, 134
 polymorphism, 136
 tissue distribution and toxicity, 131
 toxicity from P-gp inhibition, 141
P-glycoprotein substrate, 134, 139
 recognition, 134
Phagocytes, 194
Pharmaceutical R&D cost, 1
Pharmacokinetics, 345
Phosphatidylcholine, 192, 196
Phosphatidylethanolamine, 200, 204
Phosphatidylglycerol, 192
Phospholipid, 192
Physiological barriers, 181
Pinocytosis, 182
PKa, 346, 352–353
Plasma membrane, 173–176
Plasma protein binding, 357–358
Plasmid DNA, 81, 87, 88, 188
Poloxamer, 188–189
Poly (ethyleneglycol)-conjugated PEI (PEG-PEI), 90
Poly (lactic-co-glycolic acid) (PLGA), 89
Polyacrylamide, 195
Polyalkylcyanoacrylates, 183, 188–189
Polyamidoamine, 89
Polyarginine, 98
Polyaspartic acid, 200–201
Polybenzyl glutamate, 191, 200
Polybenzyl-L-aspartate, 200–202
Polybutylmethacrylate, 204
Polycaprolactone, 191
Polydimethylacrylamide, 204
Polyethlenimine (PEI), 88, 89, 90
Polyethylene glycol (PEG), 101, 182–183, 185, 200–202
Polyethylene oxide, 191, 200–203
Polyglutamic acid, 183
Polyhydroxypropyl methacrylamide, 182–184, 186
Polylactic acid, 188, 200–201
Polylactide-co-glycolide, 183, 188, 201, 265
Poly-lysine, 88, 89, 98, 100, 188
Polymer conjugates, 182–187
Polymerization, 187–188
 emulsion, 187
 ring opening, 202, 204
Polyplexes, 88, 90
Polypropylene oxide, 200–201, 203
Polysorbate, 189
Polystyrene-co-maleic anhydride, 182–185
Polyvinylpyrrolidone, 191, 195
Protein nanostructure, 217
Protein transduction, 97–98
Protein-carbohydrate complexes, 226
 glycolipids, 226
 glycoprotein, 226
 HIV-1 envelope glycoprotein, 227
Protein-nucleic acid complexes, 228
 peptide nucleic acid (PNA), 228
 Ribonucleoproteins (RNPs), 228
Protein-protein complex, 226
 HIV-1 protease, 226
 HSV ribonucleotide reductase (RR), 225
 Proteoglycans, 87
Purines, 118
Pyrimidines, 118

R

- Radioimmunoconjugate, 325
- Residence time, 189
 - plasma, 182
 - tumor, 183
- Reticuloendothelial system, 187–188, 194–195, 203
- Ribozymes, 81
- Rituxan, 315

S

- Saponins, 54
 - Quil A, 57
- Sarcoma, 185, 187, 192–193, 199, 202
 - lymphosarcoma, 193
 - osteosarcoma, 193
- SGLT, 116
- Single-chain Fv (scFv), 314
- siRNA, 81
- Sister P-gp, 147
- Skin appendages, 278
- SMVT, 116
- Solubility, 347–349
- Spans (sorbitan monostearate), 199
- Spleen, 283
- Stomatitis, 196
- Stratum corneum, 279
- Structure–property relationship, 347, 359–362
- System L, 118
- SYTO 64 dye, 82

T

- T cell, 288
 - cytokines, 288
 - effector, 288
 - receptor (TCR), 289
 - regulatory, 288
 - response and manipulation, 294, 301
 - MHC class-I, 294
 - MHC class-II, 298
- T lymphocytes, 46
 - function, 46
 - memory cells, 50

- T cytotoxic cells (TC), 47
 - cytotoxic T lymphocytes (CTLs), 46

- T helper cells (TH), 47

- T_H1, 47

- T_H2, 47

- Targeted drug delivery, 1, 181, 217

- Targeting ligand, 69

- TAT, *See* Transactivating transcriptional activator

- Telomerase, 217, 228

- Toll-like receptor, 267

- Topology, 113, 122

- Transactivating transcriptional activator (TAT), 95–104

- Transcellular, 175

- Transdermal transport, 278
 - chemical enhancement, 279
 - electroporation, 280
 - electrotransport. *See* Iontophoresis
 - iontophoresis, 279
 - electromigration, 279
 - electro-osmosis, 279
 - iontophoretic delivery. *See also* Iontophoresis
 - mechanical enhancement and mechanical abrasion, 280
 - microprojection, 281
 - penetration, 281
 - tape stripping, 280
 - passive, 279
 - sonophoresis, 280
 - ultrasound. *See also* sonophoresis

- Transfection, 190–191, 195

- Transporters, 107, 355

- Tripeptide, 185

- Tropism, 81, 82

- Tumor-associated antigens (TAA), 317

V

- Vaccine, 46, 50
 - inactivated or killed, 51
 - live-attenuated, 50
 - recombinant subunit, 52
- Vaccine delivery using microparticles 265

Vascular endothelial growth factor,
181–182
Vascular leak syndrome (VLS), 330
Vascular permeability factor, 181–182
Vesicles, 192
Vesiculovacuolar organelles, 181–182
Vinblastine, 189
Vincristine, 195–196, 199
Vitamin B₁₂ transporter, 109, 112
VP22 transcription factor, 96

X

Xanthine oxidase, 185

Z

Zevalin, 315